Abstract:The use of nanozymes has become a promising auxiliary approach to "turn on" surface-enhanced Raman scattering (SERS) signals for the label-free detection of disease markers. Nevertheless, there are still major challenges to develop bifunctional nanomaterials with both excellent enzyme-like activity and high SERS performance. To this end, a novel Z-scheme MoO3-x/CuS heterojunction was first constructed as a powerful "two-in-one" substrate, which can not only catalyze leucomalachite green (LMG) to SERS-active malachite green (MG) but also serve as an efficient substrate to amplify the SERS signal of catalysate. Due to the strong interfacial coupling effect between the MoO3-x and CuS nanomaterial, which promoted the separation and transport of carriers in the heterojunction, the MoO3-x/CuS heterojunction showed higher peroxidase-like activity compared to individual components and the previously reported heterojunction nanozymes. Inspired by these results, a sandwich-type SERS immunoassay for the detection of the cerebral infarction biomarker S100 calcium-binding protein (S100B) was proposed based on the output signal of MG at 1620 cm-1. Furthermore, introducing the antifouling material chitosan on the surface of the MoO3-x/CuS heterojunction can effectively resist nonspecific protein adsorption and significantly improve the detection accuracy of the immunoassay. Therefore, the SERS immunoassay based on the MoO3-x/CuS heterojunction realized highly sensitive and selective detection of S100B in the concentration range of 0.001 to 100 ng/mL, with a low limit of detection of 0.47 pg/mL. The developed method has been successfully used for the accurate detection of S100B in clinical serum. The results showed that the level of S100B in the serum of cerebral infarction patients can be distinguished from those of healthy individuals and intracranial tumor patient controls. In addition, the acquired values of S100B in the serum of cerebral infarction patients based this strategy were well consistent with the results of electrochemiluminescence (ECL) detection with a relative error of less than ±7.3. It is expected that this work may open up a paradigm for improving detection sensitivity and accuracy for the early diagnosis and treatment monitoring of cerebral infarction in the clinic.

Colloidal gold-based immunochromatographic biosensor for quantitative detection of S100B in serum samples

Antibody-labeled gold nanoparticle based resonance Rayleigh scattering detection of S100B

A biosensor for S100B detection based on PSS-MA-GoldMag-LFIA in early clinical diagnosis of brain damage

Clinical Evaluation of Prognosis of Severe Posttraumatic Brain Injuries by Using S-100B

Application significance of S100B in the assessment of blood-brain barrier injury

Sensitively detecting mTBI biomarker S100B by using peptide-modified ratiometric fluorescent C/AuNCs nanoprobe

Serum S-100B protein as a molecular marker in severe traumatic brain injury

In Vitro Detection of S100B and Severity Evaluation of Traumatic Brain Injury Based on Biomimetic Peptide‐Modified Nanochannels

High S100B Levels in Cerebrospinal Fluid and Peripheral Blood of Patients with Acute Basal Ganglial Hemorrhage Are Associated with Poor Outcome.

Serum S-100B for mild traumatic brain injury: a systematic review and meta-analysis of diagnostic test accuracy

Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury

Relationship between cerebrospinal fluidα-Synuclein and prognosis of patients with traumatic brain injury

A Sensitive Microchip-Based Immunosensor for Electrochemical Detection of Low-Level Biomarker S100b

The quantitative analysis of S100 in the brain tissue and serum following diffusebrain injury in rats

Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain Injury Dynamics: A Systematic Review

S100 Protein and Brain Injury Induced by Extracorporeal Circulation

Effect of Non-Cerebral Trauma on the Value of Serum S100B

Nanoporous Carbon Immunosensor for Highly Accurate and Sensitive Clinical Detection of Glial Fibrillary Acidic Protein in Traumatic Brain Injury, Stroke, and Spinal Cord Injury

The S100B story: from biomarker to active factor in neural injury

Bifunctional MoO3- x/CuS Heterojunction Nanozyme-Driven "Turn-On" SERS Signal for the Sensitive Detection of Cerebral Infarction Biomarker S100B

A specific and sensitive ELISA for measuring S-100b in cerebrospinal fluid